Linezolid Dosing for Pneumonia
For adults with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) requiring MRSA coverage, administer linezolid 600 mg IV or PO every 12 hours. 1, 2
Standard Dosing Regimen
The evidence-based dosing for pneumonia is straightforward:
- Adults: 600 mg IV or PO every 12 hours (q12h) 1, 2
- Pediatrics (birth to 11 years): 10 mg/kg IV or PO every 8 hours, not to exceed 600 mg/dose 2
- Pediatrics (≥12 years): 600 mg IV or PO every 12 hours 2
The 2016 IDSA/ATS HAP/VAP guidelines explicitly recommend linezolid 600 mg IV q12h as one of two preferred agents (alongside vancomycin) for empiric MRSA coverage in HAP 1. This dosing carries a strong recommendation with AI/AII evidence quality for pneumonia specifically 2.
Route of Administration
Oral and IV formulations are bioequivalent - linezolid has approximately 100% oral bioavailability, allowing seamless transition between routes without dose adjustment 3. This flexibility is particularly valuable for de-escalation or outpatient transition.
Duration of Therapy
Standard treatment duration is 7-14 days for HAP/VAP 4. Extend to 3 weeks if concurrent bacteremia is documented 2.
Renal Insufficiency Adjustments
Critical caveat: While the parent drug linezolid does not require dose adjustment in renal impairment, recent evidence challenges the traditional "no adjustment needed" approach 3, 5:
- Normal renal function or mild impairment (CrCL >60 mL/min): 600 mg q12h 6, 5
- Moderate impairment (CrCL 30-60 mL/min): Consider 300-450 mg q12h 6, 5
- Severe impairment (CrCL <30 mL/min): 200-300 mg q12h 6, 5
- Augmented renal clearance (critically ill): May require 600 mg q8h 6
The FDA label states no adjustment is necessary 3, but this recommendation predates pharmacokinetic data showing metabolite accumulation and increased toxicity risk in renal dysfunction 5. Therapeutic drug monitoring (TDM) is strongly advised in renal insufficiency to maintain trough concentrations (Cmin) between 2.6-7.8 mg/L 6, 5.
Infusion Duration Considerations
While standard practice uses 30-120 minute infusions, emerging evidence suggests prolonged intermittent infusion (2-5 hours) may optimize the therapeutic index for high-MIC pathogens (MIC ≥2 mg/L) requiring higher doses 7. However, avoid continuous infusion - it eliminates the concentration nadir needed to prevent toxic accumulation, particularly at moderate-to-high doses 7.
Continuous vs. Intermittent Infusion
One prospective RCT found continuous infusion (600 mg loading dose, then 1200 mg/day at 50 mg/hour) superior to standard intermittent dosing for clinical cure and safety in critically ill patients 8. However, this conflicts with pharmacokinetic modeling showing toxicity risks with continuous infusion 7. Until further validation, standard intermittent dosing remains the evidence-based approach per guidelines 1, 2.
Clinical Efficacy Data
A prospective RCT demonstrated linezolid achieved 57.6% clinical success versus 46.6% for vancomycin in MRSA nosocomial pneumonia (p=0.042), with similar 60-day mortality but less nephrotoxicity 4. In patients with renal impairment, linezolid showed 59% clinical cure versus 47% for vancomycin 9.
Safety Monitoring
Monitor for hematologic toxicity, particularly thrombocytopenia and anemia, which increase with:
- Treatment duration >14 days
- Renal insufficiency (metabolite accumulation) 3, 5
- Supratherapeutic trough levels (>8 mg/L) 6, 5
Obtain baseline and weekly CBC. Target Cmin <8 mg/L to minimize toxicity while maintaining efficacy (AUC24/MIC ≥100) 6, 5.
Common Pitfalls
- Failing to adjust for renal dysfunction: Despite FDA labeling, dose reduction prevents metabolite accumulation and toxicity 5
- Prolonging therapy unnecessarily: Toxicity risk escalates beyond 14 days
- Ignoring TDM: Particularly critical in critically ill patients with augmented renal clearance or renal impairment 6, 5
- Using continuous infusion indiscriminately: May increase toxicity without efficacy benefit 7